← Back
Data updated: Mar 10, 2026
BH
OncologyInfectious DiseaseImmunology
BH is a generic drug manufacturer focused on Oncology, Infectious Disease, Immunology.
1976
Since
1
Drugs
-
Trials
0
Approved (2yr)
Key Drugs
No active drugs
Recent Activity
No recent activity
SEC Filings
Pro
Loading...
Therapeutic Focus
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Oncology 44%
0 drugs Phase 3: 17 Phase 2: 31 Phase 1: 57
Infectious Disease 20%
0 drugs Phase 3: 12 Phase 2: 11 Phase 1: 14
Immunology 19%
0 drugs Phase 3: 14 Phase 2: 7 Phase 1: 12
Ophthalmology 9%
0 drugs Phase 3: 7 Phase 2: 3 Phase 1: 4
Cardiovascular 7%
0 drugs Phase 3: 2 Phase 2: 10 Phase 1: 3
Pipeline Strength Pro
Loading...
Competitors Pro
Novartis big-pharma
Oncology, Cardiovascular, Immunology, Ophthalmology
Merck big-pharma
Oncology, Infectious Disease, Cardiovascular, Immunology
Baxter specialty
Infectious Disease, Cardiovascular, Oncology, Ophthalmology
AbbVie big-pharma
Immunology, Oncology, Infectious Disease, Ophthalmology
Johnson & Johnson big-pharma
Oncology, Immunology, Infectious Disease, Cardiovascular
Active (0)
Discontinued (1)
Company Info
- First Approval
- 1976-07-14
- Latest
- 1976-07-14
- Applications
- 1